Approved for use through 10/31/99. OMB 0654-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE applied to respond to a collection of information unless it contains a valid OMB control number.

Under the Paperwork Reduction Act of 1995 honorsons

11


Complete if Known MAY 0 7 2004 Substitute for form 1449B/PTO **Application Number** 09/896522 June 28, 2001 Filing Date Glucksmann, Maria A. First Named Inventor 1652 **Group Art Unit** Swope, Sheridan **Examiner Name** (use as many sheets as necessary) MPI00-282P1RM **Attorney Docket Number** of

Sheet 1	l	of 1
		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS
		At the CADTIAL LETTERS) title of the article (when appropriate), title tielli
	Cite No. ¹	(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volunterssue number(s), positional
	A1 (Corby, N., Rp11-334J6 is from the library RPCI-11.2 constructed by the group of Pieter de Jong – Human DNA sequence from clone RP11-334J6 on chromosome 9, June 8, 2000 (sequence) EMBL Sequence Library [online] Heidelberg, Germany: European Molecular Biology Laboratory, Retrieved from the internet: URL: http://SRS6.EBI.AC.UK/SRS6BIN/CGI-BIN/WGETZ?-E+ EMBL-ID:AL358781] EMBL Accession No. AL358781.
4 5	A2	Isogai, T. et al., NEDO human cDNA sequencing project – Homo sapiens cDNA PL312235 its, clone MAMMA1001476, highly similar to URIDINE KINASE (EC2.7.1.48), September 29, 2000 (sequence) EMBL Sequence Library [online] Heidelberg, Germany: European Molecular Biology Laboratory, retrieved from the internet: URL: http://SRS6.EBI.AC.UK/SRS6BIN/CGI-BIN/WGETZ?-E+[EMBL-PARCENTAT FARRI Associate No. AK022317
8		Univ. Fudan, Section Ch, Week 2001144, March 14, 2001, WPI database, London, GB: Derwent Publications Ltd., Class B04, WPI Accession No. 2001-409529. Drake, J. C. et al, "Characteristics of the enzyme uridine-cytidine kinase isolated from a cultured and the control of the enzyme unidine-cytidine kinase isolated from a cultured and the control of the enzyme unidine-cytidine kinase isolated from a cultured and the control of the enzyme unidine-cytidine kinase isolated from a cultured and the control of the enzyme unidine-cytidine kinase isolated from a cultured and the control of the enzyme unidine-cytidine kinase isolated from a cultured and the control of the enzyme unidine-cytidine kinase isolated from a cultured and the control of the enzyme unidine-cytidine kinase isolated from a cultured and the control of the enzyme unidine-cytidine kinase isolated from a cultured and the control of the enzyme unidine-cytidine kinase isolated from a cultured and the control of the enzyme unidine-cytidine kinase isolated from a cultured and the control of the enzyme unidine-cytidine kinase isolated from a cultured and the control of the enzyme unidine-cytidine kinase isolated from a cultured and the control of the enzyme unidine-cytidine kinase isolated from a cultured and the control of the control of the enzyme unidine-cytidine kinase isolated from a cultured and the control of the contro
95	A4	human cell line*, Biochemical Pharmacology, 26(1):64-66 (January 1, 1977).
	·	
·		
	1	
Examiner Signature		Date Considered 717 04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation design number. ²Applicant is to place a check mark here is English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.



Form PTO-1449					Docket Number 38155200	Application Number 09/896,522					
PORTO-1449 IN AN APPLICATION (Use several sheets if necessary)					Applicant Maria A. GLUCKSMANN						
					Filing Date June 28, 2001		Group Art Unit	Group Art Unit 1645			
					Mailing Date September 2	RECEIVE					
TRADEMAN					<u>. </u>			OCT 1			
							TEC	H CENTEF	R 1600/2		
Examiner Initials	miner Ref. Date Document No.		IEN	Name Class		Subclass Filing Date					
			FOREIGN I	PAT	ENT DOCUMENT	îs					
Examiner Initjals	Ref. No.	Date	Document No.		Country	Class	Subclass	Transl YES	ation NO		
95.	1.	08/1999	WO 99/38972	W	0						
915	2.	02/2001	EP 1074617A	EP					<u> </u>		
95	3.	07/2001	WO 01/53312	W	0						
\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\	4.	08/2001	WO 01/55367	W	<u> </u>	V					
Examiner Initials	Ref. No.	Title	at al. (1979) Cance	or Ro	search 39(8):3102-31	106 -					
22	5. 6.	Ahmed, N.K. et al. (1979) Cancer Research 39(8):3102-3106 Connolly, G.P. et al. (1999) Trends in Pharmacological Sciences 20(5):218-225									
X 2	7.	Database EMBL Sequence Library [Online], retrieved from HTTP://SRS6.EBI.AC.UK/SRS6BIN/CGI-BIN/WGETZ? -E+[EMBL-ID:AL358781] Database Al AL358781, XP002202931									
\$	8.	Database EMBL Sequence Library [Online], retrieved from HTTP://SRS6.EBI.AC.UK/SRS6BIN/CGI-BIN/WGETZ?-E+[EMBL-ID:AK022317] Database AN. AK022317, XP002202932 - Z9-SEP-Z000 & F 17 04									
\$5	9	Database WPI, Section Ct, Week 200144, Derwent Publications Ltd., London, GB Class B04, AN 2001-409529, XP002202933									
MONG	10.	Van Rompay, A. et al. (2001) Molecular Pharmacology 59(5):1181-1186									
A5	11.	(1977) Bioc	hemical Pharmacolog	gy 20	5:64-66 - <u>Sea</u>	1449 c	+ 5/7/	2004			
			LONGUR		715	F/4	•				
EXAMINER: WOOD					DATE CONSIDERED: 12/22/03						
EXAMIN	ER: Initi	al if citation cons	idered, whether or not the	e citat	ion conforms with MPEP	609. Draw a	line through the	citation if no	ot in		

PTO/SB/ 08 (2-92) sd-110527 Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE